Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.33
- Piotroski Score 1.00
- Grade Buy
- Symbol (CASI)
- Company CASI Pharmaceuticals, Inc.
- Price $5.96
- Changes Percentage (-0.83%)
- Change -$0.05
- Day Low $5.95
- Day High $6.43
- Year High $8.48
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.28
- Trailing P/E Ratio -1.52
- Forward P/E Ratio -1.52
- P/E Growth -1.52
- Net Income $-26,938,000
Income Statement
Quarterly
Annual
Latest News of CASI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
NASCAR 2024 playoffs at Kansas: Start time, TV, streaming, lineup for Hollywood Casino 400
The spring race at Kansas Speedway saw Kyle Larson win by 0.001 seconds in the closest NASCAR finish ever. Larson, leading the playoff standings, aims for another victory at Kansas, where Denny Hamlin...
By USA Today | 1 day ago -
A tiny tribe is getting pushback for betting big on a $600M casino in California's wine country
The Koi Nation, a small tribe in Northern California, is partnering with the Chickasaw Nation to build a casino on land in Sonoma County, pending approval from the U.S. Department of Interior....
By Yahoo! Finance | 2 days ago -
Honorary Pace Car Driver Confirmed for NASCAR Hollywood Casino 400
Carl Edwards, set for NASCAR Hall of Fame induction in 2025, will drive the pace car at the Hollywood Casino 400 at Kansas Speedway. Known for his success at the track, this honor highlights his legac...
By Newsweek | 2 days ago
